These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 8826903)

  • 21. Plasma collagen cofactor correlates with von Willebrand factor antigen and ristocetin cofactor but not with bleeding time.
    Aihara M; Kimura A; Chiba Y; Yoshida Y
    Thromb Haemost; 1988 Jun; 59(3):485-90. PubMed ID: 3142084
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, haemate-P/humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease.
    Lillicrap D; Poon MC; Walker I; Xie F; Schwartz BA;
    Thromb Haemost; 2002 Feb; 87(2):224-30. PubMed ID: 11858481
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Successful treatment of patients with von Willebrand disease using a high-purity double-virus inactivated factor VIII/von Willebrand factor concentrate (Immunate).
    Auerswald G; Eberspächer B; Engl W; Güthner C; Koksch M; Kreuz W; Nimtz A; Pindur G; Scheel H; Schreiber JD; Siekmann J; Turecek PL; Wolf HH
    Semin Thromb Hemost; 2002 Apr; 28(2):203-14. PubMed ID: 11992243
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of Von Willebrand factor (VWF) activity VWF:Ac with VWF ristocetin cofactor activity VWF:RCo.
    Geisen U; Zieger B; Nakamura L; Weis A; Heinz J; Michiels JJ; Heilmann C
    Thromb Res; 2014 Aug; 134(2):246-50. PubMed ID: 24891215
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of a factor VIII-von Willebrand factor concentrate 8Y: stability, bacteriological safety, pharmacokinetic analysis and clinical experience.
    Lubetsky A; Martinowitz U; Luboshitz J; Kenet G; Keller N; Tamarin I; Inbal A
    Haemophilia; 2002 Sep; 8(5):622-8. PubMed ID: 12199669
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Type II H von Willebrand disease: new structural abnormality of plasma and platelet von Willebrand factor in a patient with prolonged bleeding time and borderline levels of ristocetin cofactor activity.
    Federici AB; Mannucci PM; Lombardi R; Lattuada A; Colibretti ML; Dent JA; Zimmerman TS
    Am J Hematol; 1989 Dec; 32(4):287-93. PubMed ID: 2510503
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dominant von Willebrand disease type 2A groups I and II due to missense mutations in the A2 domain of the von Willebrand factor gene: diagnosis and management.
    Michiels JJ; van Vliet HH
    Acta Haematol; 2009; 121(2-3):154-66. PubMed ID: 19506362
    [TBL] [Abstract][Full Text] [Related]  

  • 28. von Willebrand factor/factor VIII concentrate (Humate-P) for management of elective surgery in adults and children with von Willebrand disease.
    Gill JC; Shapiro A; Valentino LA; Bernstein J; Friedman C; Nichols WL; Manco-Johnson M
    Haemophilia; 2011 Nov; 17(6):895-905. PubMed ID: 21535320
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A two-centre comparative evaluation of new automated assays for von Willebrand factor ristocetin cofactor activity and antigen.
    Stufano F; Lawrie AS; La Marca S; Berbenni C; Baronciani L; Peyvandi F
    Haemophilia; 2014 Jan; 20(1):147-53. PubMed ID: 24028703
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Presurgical pharmacokinetic analysis of a von Willebrand factor/factor VIII (VWF/FVIII) concentrate in patients with von Willebrand's disease (VWD) has limited value in dosing for surgery.
    Di Paola J; Lethagen S; Gill J; Mannucci P; Manco-Johnson M; Bernstein J; Nichols WL; Bergman GE
    Haemophilia; 2011 Sep; 17(5):752-8. PubMed ID: 21689209
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dominant von Willebrand disease type 2M and 2U are variable expressions of one distinct disease entity caused by loss-of-function mutations in the A1 domain of the von Willebrand factor gene.
    Gadisseur A; van der Planken M; Schroyens W; Berneman Z; Michiels JJ
    Acta Haematol; 2009; 121(2-3):145-53. PubMed ID: 19506361
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Heterogeneous phenotypes of platelet and plasma von Willebrand factor in obligatory heterozygotes for severe von Willebrand disease.
    Mannucci PM; Lattuada A; Castaman G; Lombardi R; Colibretti ML; Ciavarella N; Rodeghiero F
    Blood; 1989 Nov; 74(7):2433-6. PubMed ID: 2804373
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Von Willebrand's disease: case report and review of literature.
    Echahdi H; El Hasbaoui B; El Khorassani M; Agadr A; Khattab M
    Pan Afr Med J; 2017; 27():147. PubMed ID: 28904675
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3.
    Michiels JJ; Gadisseur A; van der Planken M; Schroyens W; van de Velden A; Berneman Z
    Semin Thromb Hemost; 2006 Sep; 32(6):636-45. PubMed ID: 16977574
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness of high-dose intravenous immunoglobulin in a case of acquired von Willebrand syndrome with chronic melena not responsive to desmopressin and factor VIII concentrate.
    Castaman G; Tosetto A; Rodeghiero F
    Am J Hematol; 1992 Oct; 41(2):132-6. PubMed ID: 1415174
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and efficacy of continuous infusion of a combined factor VIII-von Willebrand factor (vWF) concentrate (Haemate-P) in patients with von Willebrand disease.
    Lubetsky A; Schulman S; Varon D; Martinowitz U; Kenet G; Gitel S; Inbal A
    Thromb Haemost; 1999 Feb; 81(2):229-33. PubMed ID: 10063997
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Time to think outside the box? Proposals for a new approach to future pharmacokinetic studies of von Willebrand factor concentrates in people with von Willebrand disease.
    Favaloro EJ; Kershaw G; McLachlan AJ; Lloyd J
    Semin Thromb Hemost; 2007 Nov; 33(8):745-58. PubMed ID: 18175280
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New treatments of von Willebrand disease: plasma derived von Willebrand factor concentrates.
    Menache D; Aronson DL
    Thromb Haemost; 1997 Jul; 78(1):566-70. PubMed ID: 9198217
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Laboratory diagnosis of congenital von Willebrand disease.
    Budde U; Drewke E; Mainusch K; Schneppenheim R
    Semin Thromb Hemost; 2002 Apr; 28(2):173-90. PubMed ID: 11992241
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The von Willebrand factor.
    Rodeghiero F; Castaman G
    Ric Clin Lab; 1990; 20(2):143-53. PubMed ID: 2196663
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.